Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 16, 2009

Primary Completion Date

November 8, 2011

Study Completion Date

June 19, 2020

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

BIBF 1120

VEGF inhibitor

DRUG

sunitinib

VEGF inhibitor

Trial Locations (15)

7624

University of Pecs Medical School, Dept. of Oncotherapy, Pécs

18009

Municipal Establishment Cherkasy Oncology Centre, Cherkasy

49102

"Munic.Instit.City Clin.Hosp.#4 of Dnipro City Council", Dnipropetrovks

58013

Bukovynsk State Medical University, Chernivtsi

79031

CI of LRC Lviv Onco.Reg.Treat.&Diag.Cent., Lviv

88000

Uzhgorod National University, Oncology Centre, Uzhhorod

200347

Sf. Nectarie Oncology Center, Craiova, Craiova

200385

ONCOLAB SRL, Craiova, Craiova

20-099

Ziemia Lubelska Oncological Center, Lublin, Lublin

02-781

Onco.Cent. - Instit. of Maria Sklodowskiej-Curie, Warsaw

010825

Military Central Clinical Emergency Hospital, Bucharest

CB2 0QQ

Addenbrooke's Hospital, Cambridge

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

GU2 7WG

Surrey Cancer Research Institute, Guildford

LS9 7TF

St James's University Hospital, Leeds

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY